Circulating CD40 and sCD40L Predict Changes in Renal Function in Subjects with Chronic Kidney Disease

Area of Science:

• Nephrology
• Immunology
• Biomarkers

Background:

• Soluble CD40 ligand (sCD40L) is linked to renal injury.
• Soluble CD40 receptor (sCD40R) acts as a competitive antagonist to CD40 activation.
• Chronic kidney disease (CKD) involves complex pathophysiological mechanisms.

Purpose of the Study:

• To investigate if plasma sCD40L and sCD40R levels predict renal function changes in CKD patients.
• To determine the association between sCD40L, sCD40R, and estimated glomerular filtration rate (eGFR) decline.
• To explore the potential of sCD40R as a therapeutic target in CKD.

Main Methods:

• Analysis of plasma sCD40L and sCD40R levels in an all-cause CKD cohort.
• Stratification of subjects based on sCD40L and sCD40R levels, individually and combined.
• Statistical analysis to assess the association with changes in eGFR over a 1-year follow-up period.

Main Results:

• Elevated sCD40L levels were directly associated with eGFR decline.
• Reduced sCD40R levels were negatively associated with eGFR decline.
• High sCD40L and low sCD40R independently predicted a significant decline in eGFR at 1-year follow-up (-7.57% and -6.39%, respectively).

Conclusions:

• Circulating sCD40L and sCD40R levels are associated with renal function changes in CKD.
• The CD40 decoy receptor, sCD40R, shows potential as a therapeutic target to mitigate renal function decline.
• These biomarkers may aid in predicting CKD progression and guiding treatment strategies.